The board of directors of Tong Ren Tang Technologies Co. Ltd. announced that Beijing Tong Ren Tang Chinese Medicine Company Limited (Tong Ren Tang Chinese Medicine) recently received the Certificate of Registration of Proprietary Chinese Medicine issued by the Chinese Medicine Council of Hong Kong, allowing "Danggui Buxue Keli [Tong Ren Tang]" to be sold in Hong Kong. Certificate validity period: Until 25 April 2029.

The function and main indications of the "Danggui Buxue Keli [Tong Ren Tang]" are to tonify qi and engender blood. It is used to treat fever caused by patterns of blood deficiency and floating yang. The symptoms include fever with a red complexion, vexation and thirst with a desire to drink.

The pulses are surging, large, and deficient; however, forceless pulses appear whilst under heavy pressure. As of the date of this announcement, Tong Ren Tang Chinese Medicine has cumulatively invested approximately HKD 800,000 (unaudited) in the research and development of "Danggui Buxue Keli [Tong Ren Tang]". This product has not yet been launched for sales in market.

Upon obtaining the Certificate of Registration of Proprietary Chinese Medicine issued by the Chinese Medicine Council of Hong Kong, "Danggui Buxu Keli [Tong Ren Tang[" produced by Tong Ren Tang Chinese Medicine can be sold in Hong Kong, which is conducive to expanding the product lines of the Group and beneficial to the market expansion of the Group. The obtaining of the aforementioned certificate of registration will not have any material impact on the production, operation and performance of the Group for the time being. The sales of pharmaceutical products can be influenced by factors such as change in the policy environment, exchange rate fluctuations and market competition in the Hong Kong region.